Temozolomide Clinical Trials

78 actively recruiting trials across 27 locations

▼ -2 trials since August 2026

Also known as: Adjuvant temozolomide; Adjuvant TMZ, CCRG-81045, Concurrent temozolomide; Concurrent TMZ, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo- +17 more

Pipeline

Early 1: 4Phase 1: 16Phase 2: 25Phase 3: 10Phase 1/2: 19Phase 2/3: 1

Top Sponsors

National Cancer Institute (NCI)4
Memorial Sloan Kettering Cancer Center3
Mayo Clinic3
M.D. Anderson Cancer Center3
University of California, San Francisco2

Indications

Cancer78
Glioblastoma20
Neuroblastoma8
Glioblastoma, IDH-Wildtype7
Glioblastoma Multiforme5

Other22 trials

5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.

Phase 1/2

5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours

Phase 1/2

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Phase 2

A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase 1/2

ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids

Phase 2

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Phase 2

Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

Phase 3

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Phase 1/2

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Phase 1/2

Glutamate Inhibitors in Glioblastoma

Phase 1/2

Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression

Phase 2

Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

Phase 3

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Phase 1/2

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Phase 1/2

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Phase 2

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide

Phase 2

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Early 1

Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer

Phase 2

Safety and Effectiveness Evaluation of Temozolomide (Amitzo, NanoAlvand) in Patients With Grade III and IV Glioma Tumors

Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

Phase 1/2

The Sagittarius Trial

Phase 3

Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma

Phase 2

Birmingham, Alabama8 trials

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Childrens Hospital of Alabama

Phase 2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

University of Alabama at Birmingham

Phase 2/3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Children's Hospital of Alabama

Phase 3

Embryonal Tumor With Multilayered Rosettes

University of Alabama at Birmingham

Phase 2

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

University of Alabama at Birmingham

Phase 1

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

University of Alabama at Birmingham

Phase 2

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

University of Alabama at Birmingham (Children's of Alabama)

Phase 1

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

University of Alabama/Children's of Alabama

Phase 1/2

Phoenix, Arizona5 trials

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Mayo Clinic Hospital

Phase 3

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Mayo Clinic in Arizona

Phase 1

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Mayo Clinic

Phase 3

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

Mayo Clinic Arizona

Phase 3

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Mayo Clinic Hospital in Arizona

Phase 1/2

Chicago, Illinois4 trials

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Northwestern Memorial Hospital

Phase 1/2

Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer

University of Illinois Cancer Center

Phase 2

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Northwestern University

Phase 1

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

Ann & Robert H. Lurie Children's Hospital of Chicago

Phase 1/2

Scottsdale, Arizona3 trials

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

HonorHealth Scottsdale Osborn Medical Center

Phase 3

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

HonorHealth Research Institute

Phase 1

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

Mayo Clinic in Arizona

Phase 2

Los Angeles, California3 trials

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

University of Southern California

Phase 1/2

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Children's Hospital Los Angeles

Phase 2

Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma

University of California, Los Angeles (Data Collection Only)

Phase 1

Boston, Massachusetts3 trials

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Boston Children's Hospital

Phase 1

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Brigham and Women's Hospital

Phase 1

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Boston Children's Hospital

Phase 1/2

Houston, Texas3 trials

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

M D Anderson Cancer Center

Phase 1

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

M D Anderson Cancer Center

Phase 2

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

M D Anderson Cancer Center

N/A

Irvine, California2 trials

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 3

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 1/2

Palo Alto, California2 trials

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Lucille Packard Children's Hospital Stanford

Phase 1/2

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Stanford University

Phase 2

San Francisco, California2 trials

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Local Institution - 0096

Phase 2

The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

University of California, San Francisco

Aurora, Colorado2 trials

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

University Of Colorado

Phase 2

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Children's Hospital Colorado

Phase 2

Miami, Florida2 trials

Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Baptist Health Herbert Wertheim Cancer Institute

Phase 2

STARLITE for Unresectable High-Grade Gliomas

University of Miami

Phase 1

Baltimore, Maryland2 trials

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Johns Hopkins Medical Institution

Phase 1

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2

New York, New York2 trials

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Lenox Hill Brain Tumor Center

Phase 1/2

Huntsville, Alabama1 trial

Pan Tumor Rollover Study

Local Institution - 0220

Phase 2

Anchorage, Alaska1 trial

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Anchorage Associates in Radiation Medicine

Phase 2

Bakersfield, California1 trial

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

AIS Cancer Center at San Joaquin Community Hospital

Phase 3

Augusta, Georgia1 trial

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Augusta University, Georgia Cancer Center

Phase 1

Peoria, Illinois1 trial

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

OSF Saint Francis Medical Center

Phase 1

Bethesda, Maryland1 trial

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

National Institutes of Health Clinical Center

Phase 1

Rochester, Minnesota1 trial

Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease

Mayo Clinic in Rochester

Early 1

St Louis, Missouri1 trial

Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma

Washington University School of Medicine

Early 1

Omaha, Nebraska1 trial

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

University of Nebraska Medical Center

Phase 1

Basking Ridge, New Jersey1 trial

A Study of 177Lu-PSMA-617 in People With Gliomas

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

Cincinnati, Ohio1 trial

Study of Letrozole in Recurrent Gliomas

University of Cincinnati

Early 1

Cleveland, Ohio1 trial

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

University Hospitals Cleveland Medical Center

Phase 2

Columbus, Ohio1 trial

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Ohio State University Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.